CliffBio
small molecule

LOCAMETZ

GALLIUM GA-68 GOZETOTIDE

Loss of exclusivityMarch 2036latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameLOCAMETZ
Active ingredientGALLIUM GA-68 GOZETOTIDE
StrengthN/A
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2022
Marketing statusRX

Listed patents

PatentExpiresType
12109277March 2036use U-4002
11369590August 2028substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found